PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

DISEASE CHARACTERISTICS: Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy Chronic, accelerated, or blastic phase disease May have T315I mutation in BCR-ABL kinase Relapsed after prior imatinib mesylate or c-ABL therapy No CNS leukemia PATIENT CHARACTERISTICS: ECOG performance status 0-2 Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week) Transaminases ≤ 2.5 times upper limit of normal (ULN) Bilirubin ≤ 1.5 times ULN Creatinine ≤ 1.5 times ULN No known history of HIV infection No active uncontrolled infection No grade 3 or 4 bleeding LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography No medical or psychiatric condition or laboratory abnormalities that would limit study compliance or increase risk during study participation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 90 (female) or 180 (male) days after completion of study treatment No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable angina) within the past 6 months No major thromboembolic event within the past 6 months, including any of the following: Myocardial infarction Stroke Transient ischemic attack Pulmonary embolism Noncatheter-related deep-vein thrombosis PRIOR CONCURRENT THERAPY: Recovered from all acute toxic effects (excluding alopecia) of prior therapy More than 2 weeks since prior chemoimmunotherapy Hydroxyurea must be discontinued 1 day prior to study therapy More than 4 weeks since prior major surgery No other concurrent approved or investigational anticancer treatment, including chemotherapy, biologic response modifiers, hormones, or immunotherapy No other concurrent investigational drugs No concurrent participation in another treatment clinical trial